The MPP focuses on increasing access to HIV, hepatitis C and tuberculosis medicines. Since our creation in 2010, we have published a list of priority HIV treatments for our licensing programme. In 2017, we expanded our evaluation to include important treatments for hepatitis C. Our method for prioritising, developed with support from a broad range of experts, is based on four criteria:
Target medicines may include those already in the market as well as investigational candidates. The focus is on medicines that are not yet licensed to the MPP.
The 2018 Prioritisation Report selected one HIV, one hepatitis C and three tuberculosis compounds that, if successfully developed, could improve standard of care for people living in developing countries.
*The MPP signed a licence agreement with AbbVie for glecaprevir/pibrentasvir in November 2018: more information
In addition, the following HIV products have been included in an MPP Watchlist:
|rilpivirine long-acting injectable|
The status of negotiations on priority products will be updated on a quarterly basis in line with MPP’s Transparency Policy.